United Therapeutics Corporation
UTHR | NASDAQ
$595.43
-$3.29 (-0.55%)
Nov 2, 2026, 9:47 AM ET · Market open
Market Data
Market Cap $25.54B
Enterprise Value $23.02B
Beta 0.56
Average Volume 634.08K
Shares Outstanding (Diluted) 45.8M
Shares Change YoY -5.18%
Institutional Ownership 98.66%
Exchange NASDAQ
ISIN US91307C1027
Price Performance
Price Change 1M 9.9%
Price Change 3M 15.3%
Price Change 6M 2.4%
Price Change YTD 22.2%
Price Change 1Y 35.7%
Price Change 3Y 165.3%
Price Change 5Y 193.0%
1M CAGR (ann.) 21.0%
1Y CAGR (ann.) 31.5%
5Y CAGR (ann.) 25.7%
All-Time CAGR 18.2%
Valuation
PE Ratio 21.45
Forward PE 17.10
PEG Ratio 2.18
Forward PEG -6.65
PS Ratio 8.14
Forward PS 7.20
PB Ratio 4.01
P/FCF Ratio 23.49
P/Adj. FCF Ratio 27.39
P/OCF Ratio 15.13
EV/Sales 7.30
EV/EBIT 14.52
EV/EBITDA 13.93
EV/FCF 21.06
Earnings Yield 4.7%
FCF Yield 4.3%
Adj. FCF Yield 3.6%
Financial Health
Net Cash $2.66B
Total Debt $0
Cash & Short-Term Investments $2.66B
Total Assets $7.22B
Current Ratio 5.73
Quick Ratio 5.41
Debt / Equity Ratio 0.00
Debt / EBITDA 0.00
Debt / FCF 0.00
OCF / Debt N/A
Interest Coverage 116.95
Altman Z-Score 22.21
Piotroski F-Score 6
Margins & Profitability
Gross Profit Margin 86.1%
Operating Profit Margin 44.5%
EBITDA Margin 53.1%
Net Profit Margin 41.6%
FCF Margin 34.6%
Adj. FCF Margin 29.7%
SBC / Revenue 4.9%
SBC Impact (per share) -14.2%
Returns
Return on Assets 18.2%
Return on Equity 20.2%
Return on Invested Capital 17.7%
Return on Capital Employed 21.2%
Return on Tangible Assets 18.4%
Historical Growth (CAGR)
Revenue CAGR 3Y 14.3%
Revenue CAGR 5Y 14.7%
Revenue CAGR 10Y 7.2%
EPS CAGR 3Y 16.4%
EPS CAGR 5Y 22.1%
EPS CAGR 10Y 3.1%
FCF CAGR 3Y 17.5%
FCF CAGR 5Y 14.3%
FCF CAGR 10Y 10.0%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 12
EPS Growth Next 3Y 15.1%
Revenue Growth Next 3Y 13.5%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) $6.01
EPS Growth Est (next Q) -16.1%
Revenue Est (next Q) $781.14M
Revenue Growth Est (next Q) -2.3%
Fair Value Estimates
Graham Number $307.16
Graham Upside -48.7%
Lynch Fair Value $616.53
Lynch Upside 3.0%
Price Target $673.67
Price Target Upside 12.5%
Cash Flow
Operating Cash Flow $1.69B
Free Cash Flow $1.09B
Adj. Free Cash Flow $937.6M
FCF Per Share $25.66
OCF Per Share $39.56
OCF/S Ratio 53.4%
Income Statement
Revenue $3.15B
Gross Profit $2.72B
Operating Income $1.4B
EBITDA $1.65B
Net Income $1.31B
EPS (Diluted) $27.91
Revenue / Employee $2.25M
Profit / Employee $936.36K
Employees 1,400
Add to Watchlist
Select watchlists to add or remove UTHR